Health
Beacon Biosignals Announces Multi-Year Expansion of Strategic Collaboration with Takeda to Advance Narcolepsy Diagnosis and Neurobiomarker Discovery
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year expansion of its strategic collaboration with Takeda, which began in 2024. This extension leverages the Beacon Platform to accelerate data-driven development of sleep biomarkers and patterns, and supports new diagnostic pathways that close longstanding care gaps for people with narcolepsy. Under the
About this update from Takeda Pharmaceutical Co. Ltd.
[{"type":"image","alt":"Beacon Biosignals","displaySize":"","headline":null,"caption":"Beacon Biosignals","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":76,"url":"https://media.zenfs.com/en/globenewswire.com/22419fa35f698e2d00ce3c9551d9cc35"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ogkUFBXpKsOSb_iazYoaGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/22419fa35f698e2d00ce3c9551d9cc35","width":300,"height":76}},"lazy":false},{"type":"text","content":"BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Beacon Biosignals, a leading neurotechnology company powering AI-driven neurodiagnostics and precision medicines for the brain, today announced a multi-year expansion of its strategic collaboration with Takeda, which began in 2024. This extension leverages the Beacon Platform to accelerate data-driven development of sleep biomarkers and patterns, and supports new diagnostic pathways that close longstanding care gaps for people with narcolepsy. Under the terms of the agreement, Beacon is eligible to receive up to $109 million in data license fees and potential development, regulatory, and commercial-based milestones, including equity participation.","length":697,"tagName":"p"},{"type":"text","content":"Narcolepsy is a rare neurological disorder that disrupts the brain’s regulation of sleep and wakefulness and is classified into two different types. While Narcolepsy type 2 (NT2) occurs when orexin levels are generally normal, Narcolepsy type 1 (NT1) is caused by a loss of orexin-producing neurons in the brain, leading to excessive daytime sleepiness, sudden muscle weakness (cataplexy), and disturbed nighttime sleep. Because symptoms overlap with conditions such as sleep apnea and other hypersomnia disorders, NT1 is frequently misdiagnosed or overlooked. As a result, many people living with NT1 endure years of testing and referrals before receiving an accurate diagnosis, and it is estimated that only about half of people living with NT1 in the U.S. are currently identified.","length":784,"tagName":"p"},{"type":"text","content":"The expanded partnership will utilize Beacon’s at-home neurodiagnostic solution and AI analytics to help address critical barriers in the pathway to narcolepsy diagnosis. Leveraging Waveband™, Beacon’s FDA-cleared at-home EEG headband, and AI-powered al...